Business Context and Reporting Period
Company: ILLUMINA, INC.
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 28, 2003
Business Overview: Illumina is a developer of next-generation tools for the large-scale analysis of genetic variation and function, utilizing proprietary BeadArray and Oligator technologies. The company provides products and services for SNP genotyping and gene expression profiling to the life sciences and pharmaceutical industries. Key products include the BeadLab high-throughput genotyping system, Sentrix arrays, and the BeadStation benchtop system.
Key Financial Metrics
| Metric | 2003 (in thousands) | 2002 (in thousands) |
|---|---|---|
| Total Revenue | $28,035 | $10,040 |
| Net Loss | $(27,063) | $(40,331) |
| Net Loss Per Share (Basic & Diluted) | $(0.85) | $(1.31) |
| Operating Cash Flow | $(18,256) | $(25,593) |
| Cash, Cash Equivalents & Investments | $32,882 | $66,294 |
| Long-Term Debt | $24,999 | $25,620 |
| Accumulated Deficit | $(117,487) | $(90,424) |
| Gross Margin (Product & Service) | 60% | 52% |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 179% to $28.0 million, driven primarily by a 348% increase in product revenue ($18.4 million) due to the sale of six BeadLab genotyping systems and related consumables. Service revenue grew 97% to $6.5 million, largely attributable to the International HapMap Project.
- Expense Reductions: Research and Development (R&D) expenses decreased 16% to $22.5 million due to the completion of development for several new products launched in 2003. However, Selling, General, and Administrative (SG&A) expenses increased 108% to $18.9 million, driven by higher legal fees related to the Applied Biosystems dispute and expanded sales infrastructure.
- Improved Loss Profile: Net loss improved by 33% to $27.1 million, reflecting revenue growth and reduced R&D spend, partially offset by increased SG&A and interest expenses.
- Liquidity: Cash and investments decreased significantly from $66.3 million to $32.9 million, primarily due to operating losses and the reclassification of restricted investments related to litigation bonds.
Guidance, Outlook, Risks, and Contingencies
- Outlook: Management expects R&D expenses to remain flat in 2004 but anticipates SG&A expenses will accelerate as the company expands sales and marketing infrastructure. The company expects to continue incurring net losses and negative cash flow for the foreseeable future.
- Product Launches: New products launched or announced include the BeadStation (medium-scale genotyping) and whole-genome gene expression BeadChips, expected to offset potential declines in BeadLab system sales.
- Legal Contingencies (Applied Biosystems): A significant dispute exists with Applied Biosystems regarding a terminated joint development agreement and patent infringement. Applied Biosystems seeks $30 million in damages and an injunction. Illumina has not accrued for potential losses but notes that an adverse outcome could materially affect operations. A $10 million advance payment from Applied Biosystems is recorded as a liability that could offset potential damages.
- Legal Contingencies (Employment Litigation): The company is appealing a $7.7 million judgment from a termination-of-employment lawsuit. Approximately $12.5 million in marketable securities are restricted as collateral for a surety bond until the appeal is resolved.
- Liquidity Risk: Based on current plans, cash and investments are sufficient to fund operations for 18 to 24 months. The company has filed a shelf registration statement to raise up to $65 million if market conditions become favorable.
Investor Verification Checklist
- Applied Biosystems Arbitration: Verify the status of the binding arbitration and potential financial exposure, including the risk of product sales prohibition.
- Restricted Cash: Confirm the amount of cash and investments restricted due to the employment litigation bond ($12.5 million) and its impact on working capital.
- Revenue Concentration: Assess reliance on the International HapMap Project (NIH grant), which accounted for a significant portion of service revenue, and the sustainability of this funding stream.
- Product Mix: Evaluate the transition from high-volume system sales (BeadLab) to new product lines (BeadStation, BeadChips) and the associated gross margin implications.
- Capital Needs: Monitor the company's cash burn rate and the potential need for equity financing within the next 18 to 24 months.